ATTORNEY DOCKET NO.: CIT1510-5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Lyapina et al.

Art Unit:

Not Yet Assigned

Parent Serial No.

10/046,961

Examiner:

Not Yet Assigned

Parent Filing Date
Serial No.:

January 14, 2002 Not Yet Assigned

Filed:

November 25, 2003

Title:

REGULATION OF TARGET PROTEIN ACTIVITY THROUGH

MODIFIER PROTEINS

Mail Stop PATENT APPLICATION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 § CFR 1.97, Applicants bring to the Examiner's attention the related parent patent application, U.S. Serial No. 10/046,961, filed January 14,2 002, which is relied upon for an earlier filing date under 35 USC § 121. For the convenience of the Examiner, copies of the PTO Forms 1449 are enclosed.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

CERTIFICATION UNDER 37 CFR §1.10						
"EXPRESS MAIL" Mailing Label Number: EV 318 740 059 US						
Date of Deposit: November 25, 2003						
I hereby certify that this correspondence is being deposited with the United						
States Postal Service as "Express Mail Post Office to Addressee" with						
sufficient postage on the date indicated above and is addressed to: Mail						
Stop PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450,						
Alexandria, VA 22313-1450.						
JASON BERRY						
(Name of Person Mailing Paper)						
N 0						
November 25, 2003						
(Signature) (Date)						
(Digniture) (Dute)						

In re Application of:

Lyapina et al.

Application No.: Not Yet Assigned

Filed: November 25, 2003

Page 2

PATENT Attorney Docket No.: CIT1510-5

No fee is deemed necessary in connection with the filing of this Information Disclosure

Statement, because it is being filed prior to the receipt of a first office action on the merits of the

above-captioned application. However, if any fee is required, authorization is hereby given to charge

any fees associated with the filings submitted herewith, or credit any overpayment to Deposit

Account No. 50-1355. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: November 25, 2003

Lisa A. Haile, J.D., Ph.D.

Registration No.: 38,347 Telephone: (858) 677-1456 Facsimile: (858) 677-1465

USPTO CUSTOMER NUMBER 28213

GRAY CARY WARE & FREIDENRICH LLP

4365 Executive Drive, Suite 1100

San Diego, CA 92121-2133

U.S. PATENT DOCUMENTS

EXAM. INITALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
XW	AA	6,165,731	12/26/2000	Deshaies et al.	~		

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	·						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

SH	AB	Chamovitz and Segal, "JAB1/CSN5 and the COP9 Signalsome: A Complex Situation," <i>EMBO Reports</i> , Vol. 2, No. 2, 2001, pgs. 96-101.
JAD	AC	Ciechanover, Aaron et al., "Ubiquitin-Mediated Proteolysis: Biological Regulation Via Destruction," <i>BioEssays</i> , Vol. 22, 2000, pgs. 442-451.
AND	AD	Glickman, Michael H. et al., "The Regulatory Particle of the Saccharomyces Cerevisiae Proteasome," <i>Molecular and Cellular Biology</i> , Vol. 18, No. 6, June 1998, pgs. 3149-3162.
Jal	AE	Groll, Michael et al., "The Eukaryotic 20S Proteaome: A Potential Target for Drug Development," In DFG-Schwerpunkt, Strktur, Funktion and Regulation des 20S/26S Ubiquitin-Proteasomesystems Kolloquium, May 23-25, 2001, Program Abstract, accessed on Internet June 20, 2002 at www.dfg-sp-ubiquitin.de.
	AF	Lyapina, Svetlana et al., "Promotion of NEDD8-CUL1 Conjugate Cleavage By COP9 Signalosome," <i>Science</i> , Vol. 292, May 18, 2001, pgs. 1382-1385.

/	لم	\sim	
EXAMINER (DATE CONSIDERED Hall
		17	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Daw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

	FORM PTO-1449		Docket No.	Serial No.:
	U.S. Department of Commerce Trademark Office	Patent and OCT 0 1 2002	CIT1510-3	10/046,961
			Applicants: Lyapina et al.	
1	SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	A MONADENIA	Filing Date:	Group Art Unit:
	DISCLOSURE STATEMENT	BY APPLICANT J	January 14, 2002	Unassigned 165

H	AG	Meiners, Silke et al., "Role of the Ubiquitin-Protease Pathway In Vascular Restenosis – Proteasome Inhibition As A New Therapeutic Approach," In DFG-Schwerpunkt, Strktur, Funktion and Regulation des 20S/26S Ubiquitin-Proteasomesystems Kolloquium, May 23-25, 2001, Program Abstract, accessed on Internet June 20, 2002 at www.dfg-sp-ubiquitin.de.
Sho	АН	Wei, Ning et al., "The COP9 Complex Is Conserved Between Plants and Mammals and Is Related to the 26S Proteasome Regulatory Complex," <i>Current Biology</i> , Vol. 8, No. 16, July 27, 1998, pgs. 919-922 and S1 and S2.

RECEIVED

OCT 03 2002

TECH CENTER 1600/2900

	4.	\bigcirc	·
EXAMINER	Int. (DATE CONSIDERED 3

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Praw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449